deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT03132155

QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma

A Phase 2 Study of AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma That Contains the Ewing Sarcoma Breakpoint Region 1-activating Transcription Factor-1 (EWSR1-ATF1) Gene Fusion

Sponsor: NantPharma, LLC

Conditions Clear Cell Sarcoma
Interventions AMG 337
Updated 14 times since 2017 Last updated: May 22, 2024 Started: Aug 29, 2018 Primary completion: Aug 13, 2021 Completion: Sep 21, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Prematurely terminated due to lack of therapeutic effect

Listed as NCT03132155, this PHASE2 trial focuses on Clear Cell Sarcoma and remains terminated or withdrawn. Sponsored by NantPharma, LLC, it has been updated 14 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~May 2017 – ~Jan 2018 · 8 months · monthly snapshot~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Sep 2018 · 2 months · monthly snapshot~Sep 2018 – ~Jul 2019 · 10 months · monthly snapshot~Jul 2019 – ~Apr 2020 · 9 months · monthly snapshot~Apr 2020 – ~Oct 2020 · 6 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Jan 2023 · 13 months · monthly snapshot~Jan 2023 – ~Jun 2024 · 17 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jun 2024 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Jan 2023 — Jun 2024 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  5. Dec 2021 — Jan 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

▶ Show 9 earlier versions

  1. Jan 2021 — Dec 2021 [monthly]

    Recruiting PHASE2

  2. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  3. Apr 2020 — Oct 2020 [monthly]

    Recruiting PHASE2

  4. Jul 2019 — Apr 2020 [monthly]

    Recruiting PHASE2

  5. Sep 2018 — Jul 2019 [monthly]

    Recruiting PHASE2

  6. Jul 2018 — Sep 2018 [monthly]

    Recruiting PHASE2

  7. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2

  8. Jan 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  9. May 2017 — Jan 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • NantPharma, LLC
Data source: NantPharma, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations